Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions

Abstract

Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis. While the safety of THC and cannabis has been extrapolated from millennia of recreational use, medical marijuana programs have increased exposure among medically complex individuals with comorbid conditions and many co-prescribed medications. Thus, THC should be recognized as a pharmacologically complex compound with potential for drug–drug interactions and adverse drug events. This review summarizes potential adverse drug events related to THC when combined with other medications. Metabolic drug–drug interactions are primarily due to THC conversion by CYP3A4 and CYP2C9, which can be impacted by several common medications. Further, CYP2C9 polymorphisms are highly prevalent in certain racial groups (up to 35% in Caucasians) and increase the bioavailability of THC. THC also has broad interactions with drug-metabolizing enzymes and can enhance adverse effects of other medications. Pharmacodynamic interactions include neurological effects, impact on the cardiovascular system, and risk of infection. General clinical recommendations for THC use include starting with low doses and titrating to desired effects. However, many interactions may be unavoidable, dose-limiting, or a barrier to THC-based therapy. Future work and research must establish sufficient data resources to capture medical marijuana use for such studies. Meanwhile, clinicians should balance the potential risks of THC and cannabis and the lack of strong evidence of efficacy in many conditions with patient desires for alternative therapy.

Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry

“…These effects are characterized as both the target effects (e.g., pain relief) that drive patients to seek therapy with cannabis as well as adverse drug events (ADEs) related to cannabis and its components (e.g., psychiatric events). These have included somnolence, sedation, acute psychiatric events (paranoia, hallucination, euphoria), cognitive and memory impairment, insomnia, gait disturbances, suicidal thoughts or behaviors, tachycardia, vertigo, and anorexia [16,21,28,29].…”

Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic

“…3 Consumer doses of CBD are likely much lower than these therapeutic doses for refractory seizures but CBD doses through medical cannabis preparations could be equally potent. 1 Thus, current pharmacological and clinical evidence suggests CBD (and the other primary cannabinoid, tetrahydrocannabinol [THC]) 4 could decrease the ability fight off infections and is contrasted against its potential clinical uses as an anti-inflammatory. This risk may be higher for viral and respiratory infections.…”

Down and High: Reflections Regarding Depression and Cannabis

“…Low doses of cannabis or its derivatives should be tested, as there is a clear signal that there is a different pharmacological effect of high and low dose. Future research should consider that this complex molecule also has the potential for drug-drug interactions (136)(137)(138)(139). The dimensions of apathy, anhedonia, cognition and anxiety will be important secondary outcomes to consider.…”